{"title":"Forma Therapeutics和Janssen Biotech联手建立7亿美元药物发现联盟，瞄准肿瘤代谢","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I2.1676","DOIUrl":null,"url":null,"abstract":"Forma Therapeutics has secured another big pharma deal by forming a cancer drug discovery alliance with Johnson & Johnson’s Janssen Biotech. Forma will discover and develop drugs against a panel of tumour metabolism targets and could receive up to US$700 M in project funding and milestone payments plus royalties. In a first for the company and contingent upon the achievement of certain milestones during the initial phase of the collaboration, Forma has an option to co-develop and retain North American rights to one of the collaboration programmes, to be selected by Janssen.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"296 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Forma Therapeutics and Janssen Biotech Target Tumour Metabolism with US$700 M Drug Discovery Alliance\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I2.1676\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Forma Therapeutics has secured another big pharma deal by forming a cancer drug discovery alliance with Johnson & Johnson’s Janssen Biotech. Forma will discover and develop drugs against a panel of tumour metabolism targets and could receive up to US$700 M in project funding and milestone payments plus royalties. In a first for the company and contingent upon the achievement of certain milestones during the initial phase of the collaboration, Forma has an option to co-develop and retain North American rights to one of the collaboration programmes, to be selected by Janssen.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"296 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I2.1676\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I2.1676","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Forma Therapeutics与强生旗下的杨森生物技术公司(Janssen Biotech)达成了另一项大型制药交易，即建立癌症药物研发联盟。Forma将发现和开发针对一组肿瘤代谢目标的药物，并可能获得高达7亿美元的项目资金、里程碑付款和版税。对于公司来说，在合作的初始阶段，根据某些里程碑的实现，Forma可以选择共同开发并保留其中一个合作项目的北美权利，由杨森选择。
Forma Therapeutics and Janssen Biotech Target Tumour Metabolism with US$700 M Drug Discovery Alliance
Forma Therapeutics has secured another big pharma deal by forming a cancer drug discovery alliance with Johnson & Johnson’s Janssen Biotech. Forma will discover and develop drugs against a panel of tumour metabolism targets and could receive up to US$700 M in project funding and milestone payments plus royalties. In a first for the company and contingent upon the achievement of certain milestones during the initial phase of the collaboration, Forma has an option to co-develop and retain North American rights to one of the collaboration programmes, to be selected by Janssen.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
